RCS - GenIP PLC - Sales and Product Update

GenipAnnouncement

10/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260210:nRSJ3014Sa&default-theme=true

RNS Number : 3014S  GenIP PLC  10 February 2026

 

 

 

10 February 2026

 

GenIP Plc

("GenIP" or the "Company")

 

Sales and Product Update

 

GenIP Plc, the AI-powered innovation intelligence and technology
commercialisation company, is pleased to report continued momentum across
corporate and academic markets, building on the operational progress detailed
in its January Corporate Update and reflecting a broadening interest in the
newer portfolio-based products Invention Prioritizer and Invention
Validator.

 

Corporate Clients

 

In line with the strategic drive to build the corporate customer base:

 

●    A Spanish innovation network serving c.12,000 businesses has adopted
the Invention Prioritizer product for its portfolio management.

●    A US Intellectual Property strategy consultancy has engaged GenIP to
support its inventor and innovation community.

 

Academic Clients

 

A UK university has expanded its use of GenIP's products beyond the Invention
Evaluator report, commissioning more in-depth, market-focused analysis to
support decisions across their technology portfolio.

 

Discussions and proposals continue with Academic Institutes across Europe,
LATAM, and the Middle East.

 

These developments with new and existing customers demonstrate that GenIP's
products are becoming embedded in the core decision making workflows of
research organisations, directly shaping how they prioritise and allocate
investment across their portfolios. This deeper integration strengthens
GenIP's commercial proposition, supporting sustained price and margin
expansion while locking in recurring revenue throughout the customer's
investment and decision cycles.

 

Innovation Exchange Webinar Series

 

In January, GenIP launched its Innovation Exchange webinar series, showcasing
how leading research institutes and organisations are rethinking technology
commercialisation strategies. The first session demonstrated how KAUST (King
Abdullah University of Science and Technology) manages its technology transfer
operations and how they use GenIP's products. The session was well attended by
over 40 organisations across four continents. It is planned that this series
will provide monthly webinars delivering substantive discussions on how to
systematically move new technologies to market. The next two sessions are
already planned, involving Universities in Puerto Rico and Brazil. Initially
free to attend, it is hoped to build this into a subscription series.

 

Panel Speaker at Industry Events

 

GenIP will be a member of a Panel discussing "Beyond Incentives: Redefining
the Value Proposition for Underserved Populations." at the Annual Meeting of
AUTM (Association of University Technology Managers) in Seattle USA in
February - the technology transfer industry's primary conference and
exhibition in the Americas. This reflects the growing profile of the Company
within the in technology transfer industry.

 

Melissa Cruz, CEO of GenIP, commented:

"This update reflects a clear evolution in how organisations are engaging with
GenIP. Repeat customers are expanding their use of our products, while new
corporate clients are adopting higher-value, portfolio-level solutions as part
of their ongoing decision-making processes.

With global R&D spending now approaching USD 3 trillion* per year, yet
fewer than 20% of innovations ultimately reaching the market, research
organisations are under increasing pressure to make faster, more disciplined
portfolio decisions.

GenIP is addressing this challenge by embedding structured portfolio
prioritisation into core innovation workflows, enabling more efficient capital
allocation and accelerating the path from research to commercial outcomes.
This is translating into growing international momentum across both academic
and corporate markets."

*Source: World Intellectual Property Organization (WIPO), Global Innovation
Index - End-of-Year Edition 2025.

 

For further information regarding GenIP, please visit www.genip.ai
(http://www.genip.ai/) , or contact:

 

 GenIP Plc                                                          Via Redchurch Communications

 Melissa Cruz, CEO

 AlbR Capital Limited (Broker)                                      Tel: +44 (0)20 7399 9427

 Colin Rowbury                                                      cr@albrcapital.com (mailto:cr@albrcapital.com)

 Jon Belliss                                                        Jb@albrcapital.com (mailto:Jb@albrcapital.com)

 Redchurch Communications (Financial PR)                            genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 John Casey

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

Notes to Editors

 

About GenIP

 

GenIP is a next-generation consultancy at the intersection of generative AI
and innovation strategy. We empower corporates, venture funds, and research
institutions to evaluate, commercialise, and scale breakthrough technologies.
By combining proprietary GenAI algorithms with expert human analysis, GenIP
delivers decision-grade insights and talent solutions that accelerate
innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 

 Service                               Description                                                                   Value Proposition
 Invention Intelligence Product Suite  AI-powered market intelligence reports assessing the commercial potential of  Enables faster, evidence-based decisions on R&D prioritisation,
                                       emerging technologies                                                         investment, and IP strategy
 Talent and Executive Search Services  Executive search platform using machine learning and NLP to match             De-risks scaling by aligning technical vision with proven executive capability
                                       innovation-driven organisations with commercialisation-ready leadership

 

Together, these services form a unified GenAI-enabled platform for innovation
triage and execution.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for
innovation commercialisation. Our strategy is anchored in three growth
pillars:

 

●    Organic Expansion

Scale Invention Evaluator and Recruitment Services through targeted outreach
to corporates, VCs, and research institutions, supported by strategic
marketing and digital engagement.

●    Service Deepening

Enhance functionality and margin by expanding GenAI capabilities within both
service lines-unlocking new use cases and customer segments.

●    Strategic Acquisitions

Pursue bolt-on acquisitions of complementary GenAI services with validated
market traction to broaden our offering and accelerate growth.

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking
statements. When used in this announcement, the words "may", "would", "could",
"will", "intend", "plan", "anticipate", "believe", "seek", "propose",
"estimate", "expect", and similar expressions, as they relate to the Company,
are intended to identify forward-looking statements. These statements include,
but are not limited to, statements regarding intentions, beliefs or current
expectations concerning, among other things, the Company's results of
operations, financial position, liquidity, prospects, growth, strategies and
expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future
events and are subject to certain risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements
to materially differ from those described in this announcement Should one or
more of these risks or uncertainties materialise, or should assumptions
underlying forward-looking statements prove incorrect, actual results may
differ materially from those described in this announcement as "intended",
"planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any
hyperlinks accessible from the Company's website are not incorporated by
reference into, and do not form part of, this announcement and investors
should not rely on them.

-ENDS-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASSEFMUEMSEFE



            Copyright 2019 Regulatory News Service, all rights reserved